Author:
Vítovcová Barbora,Skarková Veronika,Havelek Radim,Soukup Jiří,Pande Ananya,Caltová Kateřina,Rudolf Emil
Abstract
AbstractGlioblastoma multiforme (GBM) belongs to most aggressive and invasive primary brain tumor in adults whose prognosis and survival remains poor. Potential new treatment modalities include targeting the cytoskeleton. In our study, we demonstrated that repurposed drug flubendazole (FLU) significantly inhibits proliferation and survival of GBM cells. FLU exerted its effect by affecting microtubule structure and our results also suggest that FLU influences tubulins expression to a certain degree. Moreover, FLU effects decreased activation of STAT3 and also partially inhibited its expression, leading to upregulation of p53 signaling pathway and subsequent cell cycle arrest at G2/M phase as well as caspase-dependent cell death in GBM cells. These results suggest FLU as a promising agent to be used in GBM treatment and prompting further testing of its effects on GBM.
Publisher
Springer Science and Business Media LLC
Reference34 articles.
1. Ramos, A. D., Magge, R. S. & Ramakrishna, R. Molecular pathogenesis and emerging treatment for glioblastoma. World Neurosurg. 116, 495–504 (2018).
2. de Gooijer, M. C. et al. An experimenter’s guide to glioblastoma invasion pathways. Trends Mol. Med. 24(9), 763–780 (2018).
3. Strobel, H. et al. Temozolomide and other alkylating agents in glioblastoma therapy. Biomedicines 7(3), 1 (2019).
4. Miranda, A., et al. Breaching barriers in glioblastoma. Part I: Molecular pathways and novel treatment approaches. Int. J. Pharm. 531(1), 372–388 (2017).
5. Schreck, K.C., & Grossman, S.A. Role of temozolomide in the treatment of cancers involving the central nervous system. Oncology (Williston Park) 32(11), 555–60, 569 (2018).
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献